A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis Academic Article uri icon

Overview

MeSH Major

  • Amyotrophic Lateral Sclerosis
  • Fructose

abstract

  • At the dose studied, topiramate did not have a beneficial effect for patients with ALS. High-dose topiramate treatment was associated with a faster rate of decline in muscle strength as measured by MVIC and with an increased risk for several adverse events in patients with ALS. Given the lack of efficacy and large number of adverse effects, further studies of topiramate at a dose of 800 mg or maximum tolerated dose up to 800 mg/day are not warranted.

publication date

  • August 26, 2003

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 12939417

Additional Document Info

start page

  • 456

end page

  • 64

volume

  • 61

number

  • 4